GeneDx announced on September 18, 2025, the appointment of Dr. Thomas Fuchs, Chief AI Officer at Eli Lilly and Company, to its board of directors. Dr. Fuchs brings extensive experience in scaling AI and machine learning infrastructure for high-impact applications in diagnostic medicine.
As SVP and Chief AI Officer at Lilly, Dr. Fuchs provides strategic direction for AI initiatives across drug discovery, clinical trials, manufacturing, and commercial activities. His expertise is expected to be invaluable in helping GeneDx realize the full potential of AI to deliver faster, more precise insights to clinicians and families.
This appointment reinforces GeneDx’s strategic commitment to leveraging AI, building on recent advancements such as the Multiscore AI-powered decision support tool and the acquisition of Fabric Genomics. Dr. Fuchs's background at the intersection of AI and human health aligns with GeneDx's goal of improving patient outcomes and accelerating drug discovery and development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.